Specifically, GPC4 was found to be significantly upregulated in liver cholangiocarcinoma (CHOL), breast invasive carcinoma (BRCA), thymoma (THYM), rectum adenocarcinoma (READ), kidney renal papillary cell carcinoma (KIRP), colon adenocarcinoma (COAD), and glioblastoma (GBM) in comparison to normal healthy tissues (Figure 1, positive change in GPC4 expression above the p value threshold of 0.05). Here, GPC4 is linked to invasive breast carcinoma.